Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
IMVT Stock Chart & Stats
$22.84
-$0.80(-3.25%)
At close: 4:00 PM EST
$22.84
-$0.80(-3.25%)
Day’s Range― - ―
52-Week Range$12.72 - $29.49
Previous CloseN/A
Volume171.97K
Average Volume (3M)1.58M
Market Cap
$4.00B
Enterprise Value$2.28B
Total Cash (Recent Filing)$521.87M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Feb 18, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding175,276,520
10 Day Avg. Volume1,046,066
30 Day Avg. Volume1,584,043
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.66
Price to Sales (P/S)0.00
P/FCF Ratio-6.88
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.68
Forecast
1Y Price Target
$37.86Price Target Upside65.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe company remains in execution mode across several late-stage programs, with all clinical timelines for IMVT-1402 remaining on track.
Efficacy And Safety DataNo new safety signals were observed, which management believes bodes well for long-term treatment with IMVT-1402.
Market OpportunityOverall, the efficacy signal with FcRn inhibition in uncontrolled GD is encouraging, and the market is believed to be a multi-billion dollar opportunity.
Bears Say
Financing RisksThe company is late to the FcRn market and faces potential financing risks ahead of key value inflecting events due to limited cash reserves.
Investor SkepticismShort interest in the stock is high, with 24.1% of the float being shorted, which could indicate skepticism among investors.
Market Competition1402 is too far behind in certain indications like myasthenia gravis to gain meaningful market share, with competitor drugs already well-established.
Immunovant News
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $12.72 and its highest was $29.49 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $4.00B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Feb 18, 2026 which is in 72 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Nov 10, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.714 by -$0.016.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.72.
How many shares outstanding does Immunovant have?
Immunovant has 175,276,520 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.714. Following the earnings report the stock price went up 0.086%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
Immunovant Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.86 (65.76% Upside)
$37.86 (65.76% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 534.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $442.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.57%
12-Months-Change
Fundamentals
Return on Equity
-95.93%
Trailing 12-Months
Asset Growth
13.04%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant achievements in clinical trials, particularly for brepocitinib in dermatomyositis and batoclimab in Graves' disease, alongside a strong financial position and progress in legal proceedings. However, increasing competition in the Graves' disease market and delays in TED data release present challenges.View all IMVT earnings summariesIMVT Stock 12 Month Forecast
Average Price Target
$37.86
▲(65.76% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crinetics Pharmaceuticals
―
Mirum Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---